| Business Summary | | American
Bio
Medica
Corporation
is
primarily
engaged
in
acquiring,
developing,
manufacturing
and
marketing
biomedical
technologies
and
products.
The
Company
produces
several
versions
of
a
drugs
abuse
screening
test
called
the
Rapid
Drug
Screen.
The
Rapid
Drug
Screen
is
a
one-step
test
that
allows
a
small
urine
sample
to
be
tested
for
the
presence
or
absence
of
up
to
nine
drugs
of
abuse
--
cocaine,
THC
(marijuana),
opiates,
amphetamine,
PCP,
benzodiazepines,
methamphetamine,
barbiturates,
and
tricyclic
antidepressants
--
simultaneously. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | American
Bio
Medica
Corporation
develops,
manufactures,
and
markets
inexpensive,
accurate,
on-site
drugs
of
abuse
diagnostic
kits
and
support
services
worldwide.
For
the
fiscal
year
ended
4/30/01,
revenues
fell
2%
to
$7.5
million.
Net
loss
applicable
to
Common
fell
17%
to
$1.9
million.
Revenues
reflect
a
decrease
in
the
number
of
distributors
selling
products.
Lower
loss
reflects
a
gain
from
the
patent
litigation
settlement
and
higher
interest
income. | More
from
Market Guide: Significant
Developments |
| | |
| Position | Robert Aromando, Jr., 44 | Chairman,
CEO | Stan Cipkowski, 52 | Pres,
Director | Keith Palmer | CFO,
VP-Fin., Treasurer | Jay Bendis, 53 | VP
of Sales and Marketing | Douglas Casterlin, 53 | VP
of Operations |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|